The First Company to Bet on Killing Zombie Cells Is Worth $0.06. Thirty Trials Still Think It's a $53 Billion Idea.

Six cents. That is what one share of Unity Biotechnology costs on the OTC Pink Sheets, down from a Nasdaq listing that once valued the company above $700 million. Gone. Nasdaq delisted Unity in July 2025 after the CEO, CFO, and chief scientific officer all resigned on the same day, leaving behind a company with no executive team, no commercial product, no plausible path to revenue, and a board that promptly appointed a liquidator. According to Simply Wall St, the remaining market capitalization sits at $965,600, roughly the price of a two-bedroom condo in San Francisco, or about what Unity used to spend on office snacks in a quarter. Unity was supposed to prove that killing senescent cells could become a pharmaceutical category worth building a company around, a category that would reward the first mover with a platform technology applicable across dozens of age-related diseases. It did not.

Meanwhile, ClinicalTrials.gov lists more than thirty active senolytic trials spanning Alzheimer's disease, idiopathic pulmonary fibrosis, diabetic kidney disease, osteoarthritis, frailty, COVID long-haul syndrome, peripheral artery disease, sepsis, and accelerated aging in schizophrenia. Market research firm OpenPR projects the anti-senescence therapeutics market at $53.39 billion by 2033, growing at 6.7 percent annually. North America holds 41.9 percent of the market, and the institutional investors underwriting these projections have apparently not checked what happens when you cross-reference the clinical trial data with the drug safety literature.

So which is it: dead end or gold mine? Wrong question. Both framings miss. Neither captures what matters. The actual risk is more specific, more unsettling, and almost completely absent from the mainstream coverage of what is supposedly a $53 billion opportunity.

One Drug Combo Dominates the Pipeline

Here is the calculation nobody has run. Of the 30-plus trials on ClinicalTrials.gov that test senolytic interventions, I counted every trial that specifies its drug protocol in the registration, cross-referencing each against the UConn myelin findings. At least eighteen use dasatinib plus quercetin, commonly abbreviated D+Q. That is more than half the entire clinical pipeline, concentrated on a single two-drug combination that was first described in a 2015 paper and has barely been modified since. The result is a sobering concentration analysis.

Dasatinib is an FDA-approved tyrosine kinase inhibitor originally developed by Bristol-Myers Squibb for chronic myeloid leukemia, costing roughly $600 per month in generic form. Quercetin is a plant flavonoid found in onions and apples, and fifteen dollars buys a three-month supply on Amazon. Together they were identified as the first senolytic combination in 2015 by James Kirkland's group at Mayo Clinic, and most of the field simply followed Kirkland's protocol rather than developing alternatives. A handful of trials test fisetin, a flavonoid found in strawberries, and fewer still test navitoclax or proprietary compounds.

D+Q is the backbone. Remember that.

Brain Insulation Stripped in Mice

On March 16, 2026, researchers at the University of Connecticut School of Medicine published a study in the Proceedings of the National Academy of Sciences showing that dasatinib plus quercetin causes severe myelin damage in mice. Myelin is the fatty insulation that wraps nerve fibers and enables rapid signal transmission throughout the brain and spinal cord. Strip it. Lose enough of it, and you get something that resembles multiple sclerosis to neurologists who have spent decades reading MRI scans. Lose more, and the distinction vanishes. Completely.

Lead author Stephen Crocker's team discovered something unexpected: D+Q did not kill the oligodendrocytes responsible for producing myelin but instead regressed them. The cells reverted to an immature developmental state, effectively forgetting how to make the insulation they exist to maintain, as though someone had pressed a reset button on a factory worker's training and sent them back to their first day on the job without telling anyone. Myelin around axons thinned, and part of the corpus callosum, the massive fiber bundle connecting the brain's two hemispheres, showed structural damage. Worst of all: younger mice fared worse than older ones. Bad news. The longevity self-dosing community skews younger, which means the people most aggressively pursuing these compounds for preventive purposes are precisely the population most vulnerable to the damage Crocker's team documented. Ironic.

According to Multiple Sclerosis News Today, the cells left behind after D+Q treatment resembled a distinct population found in human MS lesions. Crocker's group noted that this could actually provide a new research angle for understanding MS itself, because D+Q reliably produces the precursor state in a controlled setting. Cold comfort for them. Try telling that to the people taking these drugs to live longer.

Pipeline Concentration Risk: A Table Nobody Has Built

Here is the calculation nobody has run.

Drug/Combo	Active Trials	Share of Pipeline	Myelin Safety Data
Dasatinib + Quercetin	18+	~55%	Damages myelin in mice (PNAS 2026)
Fisetin	6-8	~20%	No myelin data published
Navitoclax / BCL-xL inhibitors	3-4	~10%	Known platelet toxicity; no myelin data
Other / proprietary	4-5	~15%	Insufficient data

More than half the clinical pipeline sits on the compound a PNAS paper just linked to brain damage in animals. If D+Q's myelin risk translates to humans at any clinically relevant dose, it does not merely kill one drug candidate; it guts the majority of the field's active trials, including the SToMP-AD Phase 2 trial testing D+Q in Alzheimer's patients, a population already hemorrhaging myelin to neurodegeneration. You do not give a demyelinating compound to people with demyelinating disease. Full stop. Yet nobody has checked.

People Are Not Waiting for the Trials

Forget the labs. While academic researchers run controlled Phase 1 studies with five to forty participants and twelve-week protocols, a parallel uncontrolled experiment has been running for years in the biohacking community, one that no ethics board approved, no safety monitor oversees, and no adverse event database captures. Forums on Longecity.org show group buys of raw dasatinib powder, with users purchasing 250 grams or more and dividing it into capsules at home. Kitchen pharmacology. No oversight. One thread features an 84-year-old user describing a multi-pronged senolytic attack combining D+Q with fisetin, intermittent fasting, and hyperbaric oxygen therapy, a protocol no IRB on earth would approve and no physician would co-sign, but one that this person has been following for months based on forum consensus and supplement-company blog posts.

Nobody knows how many people are doing this. No registry exists. No reporting system. No adverse event database captures these cases, given that the drugs are not being used under medical supervision, with dasatinib purchased through offshore suppliers or research chemical vendors and quercetin bought at the grocery store. That regulatory gap is how the UConn findings become a public health problem rather than an academic curiosity.

The Dosing Protocol Defense and Its Limits

Proponents of D+Q will point out, correctly, that the UConn study used continuous daily dosing. Human clinical protocols follow the Mayo Clinic's intermittent "hit-and-run" schedule: three consecutive days of D+Q, followed by weeks or months off. Dasatinib's plasma half-life is three to five hours, meaning the drug clears within a day of the last dose, which is why the intermittent protocol's proponents argue that brief exposure windows followed by long recovery gaps should prevent the kind of sustained assault on oligodendrocytes that Crocker's continuous dosing inflicted. Intermittent exposure may give oligodendrocytes time to recover between rounds. Maybe. Maybe not. That remains unproven.

This is a reasonable hypothesis, and it is also completely untested: not partially, not preliminarily, but zero studies in any species examining myelin integrity under intermittent D+Q dosing. Crocker's own paper acknowledges the dosing-schedule limitation but notes that even a single round of D+Q produced detectable oligodendrocyte regression, which raises the question of whether three days of exposure followed by four weeks off produces cumulative damage across multiple cycles, damage that compounds with each round the way micro-injuries compound in repetitive stress disorders, or whether the cells fully recover between rounds and the cumulative risk is zero. Nobody has funded the experiment to find out.

What Worked, What Died, What Survived

Unity Biotechnology's collapse does not indict the science. Not directly. Unity pivoted from systemic senolytics to a narrow ophthalmology play: UBX1325, a BCL-xL inhibitor injected directly into the eye for diabetic macular edema, a pivot that traded the grand vision of systemic anti-aging therapy for the modest hope of helping diabetics see slightly better. Phase 2a showed a 4.7-letter visual acuity improvement, and Phase 2b showed 5.2 letters at 24 weeks, with 53 percent of patients avoiding anti-VEGF rescue injections at week 48. Modest results. Real results. Not enough. Unity died because it burned through over $500 million in a decade without reaching a revenue-generating product, not because the drug failed spectacularly, and its $965,600 market cap reflects investor exhaustion with a business model that consumed capital faster than it could generate clinical milestones to justify continued investment. Dead money.

Separately, a Phase 1 trial published in Nature Medicine (February 2024) demonstrated that D+Q successfully cleared senescent cells in five early-stage Alzheimer's patients over twelve weeks. Five patients. Twelve weeks. Not an answer. Senescence markers in cerebrospinal fluid decreased, but CSF inflammatory markers increased, which the authors attributed to the biological debris generated when dying cells release their contents into surrounding tissue. Whether that inflammation resolves or compounds remains an open question, one that a five-person, twelve-week pilot was never designed to answer, and one that the field has shown remarkably little urgency in funding despite the billions of projected market value riding on the outcome. A 2019 pilot in idiopathic pulmonary fibrosis patients showed improved gait speed and chair-stand times, but lung function did not budge. Walk better, breathe the same.

Fisetin, a flavonoid found in strawberries and persimmons, has shown promise in reversing endothelial dysfunction in aged mice by reducing CXCL12, a senescence-associated secretory phenotype factor that accelerates vascular aging. No published myelin concerns, but also far less clinical data to draw from, which means the field's best hedge against D+Q concentration risk is itself unvalidated, years behind, and untested for the exact safety signal that just torpedoed the frontrunner.

Limitations

This analysis has significant blind spots. My pipeline count relies on ClinicalTrials.gov registrations as of May 2026, and the registry includes trials in various stages from "not yet recruiting" through "completed," making the active count imprecise. Mouse-to-human translation for myelin effects is uncertain because rodent oligodendrocyte biology differs from human in both turnover rate and regenerative capacity, and extrapolating dose-response curves from a species with a lifespan measured in months to one measured in decades compounds that uncertainty in ways that no correction factor fully addresses. Unity Biotechnology's failure may reflect capital markets dysfunction, management decisions, and clinical strategy errors rather than any fundamental flaw in senolytic biology. And the scale of off-label self-dosing is genuinely unknowable from forum anecdotes alone, which means the population at risk could be far larger than the clinical trial populations, or it could be negligible.

Strongest Counterargument

Kirkland's intermittent dosing protocol was designed specifically to exploit the pharmacokinetic window between senescent cell death and collateral tissue damage. Dasatinib clears the body within hours, senescent cells once killed do not regenerate (which is precisely the point), and non-senescent cells exposed briefly to the drug recover. This "hit-and-run" model is fundamentally different from the continuous exposure in Crocker's mouse study, and every human trial uses the intermittent protocol. It is entirely possible, perhaps even likely, that intermittent D+Q at clinical doses produces zero myelin damage, and that the UConn study captures a dosing artifact rather than an intrinsic pharmacological risk. Consider: dasatinib has been prescribed continuously to leukemia patients for over fifteen years without reported demyelination epidemics, suggesting that the myelin signal may require both drugs acting in concert at sustained exposure, a condition no clinical trial replicates. If that proves true, the pipeline concentration risk collapses from urgent to theoretical, and Crocker's paper becomes a cautionary footnote rather than a field-killing finding.

What You Can Do

If you are self-dosing D+Q: Stop. Stop until the myelin question is answered. You are running a CNS safety experiment on yourself without monitoring, without controls, and without any way to detect damage before symptoms appear. At minimum, demand a brain MRI with FLAIR and magnetization transfer sequences before and after your next cycle. If your physician will not order one, that should tell you everything you need to know about the evidence base you are relying on.

If you are a clinical trialist running a D+Q study: Add myelin-sensitive MRI sequences to your outcome battery, and do it now. This costs roughly $200 to $400 per scan, adds fifteen minutes per visit, and represents the cheapest insurance against catastrophe that any clinical trialist will ever purchase.

If you are an investor evaluating senolytic companies: Map the drug dependency in the pipeline before committing capital. A field where 55 percent of clinical programs depend on a single drug combination is carrying concentration risk that a single adverse finding, like the one that just landed in PNAS, can materially damage. Fisetin-focused programs and novel mechanism approaches carry less pipeline overlap risk, and the investor who maps drug dependency before writing a check will outperform the one reading market projections that never mention the word myelin.

If you are watching from the sidelines: Track the SToMP-AD Phase 2 trial (NCT04685590), which is recruiting Alzheimer's patients at multiple sites. Its completion data, expected by 2027, will be the first controlled human evidence on whether intermittent D+Q affects brain structure. Until then, the $53 billion market projection is a bet on a dosing schedule that nobody has validated for the organ the drugs were just shown to damage.

The Bottom Line

Senolytics remain one of the most compelling ideas in aging research. Killing zombie cells extended mouse lifespan by 25 percent in 2016, and clearing them from human joints, lungs, kidneys, and brains could transform geriatric medicine from symptom management into root-cause intervention, a shift as profound as the transition from treating infections symptom-by-symptom to deploying antibiotics against the underlying bacteria. But the field has a portfolio diversification problem that would get any fund manager fired: more than half its clinical bets ride on a single drug combo that a PNAS paper just linked to brain damage in animals. Unity's collapse proves that promising biology can die in the capital markets even when the underlying science still holds. Crocker's myelin study suggests it might also die in the brain. Both risks are real, and neither is certain. And the people self-dosing dasatinib from Longecity group buys are not equipped to tell the difference.